Drug Profile
Alectinib - Roche
Alternative Names: AF-802; Alecensa; ALECENSARO; Alectinib hydrochloride; CH-5424802; RG-7853; RO-5424802; RO-5452802Latest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator Chugai Pharmaceutical
- Developer Chugai Pharmaceutical; National Hospital Organization Nagoya Medical Center; Roche; Seoul National University Hospital; University College London
- Class Antineoplastics; Carbazoles; Morpholines; Nitriles; Phenyl ethers; Piperidines; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Registered Anaplastic large cell lymphoma
- Phase II Solid tumours
- Phase I/II Brain cancer; Thyroid cancer
Most Recent Events
- 27 Feb 2024 Genentech completes a phase II trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO) (NCT04632992)
- 01 Feb 2024 Chugai pharmaceutical announces intention to file regulatory applications for Non-small cell lung cancer (Adjuvant therapy) in the US, EU and China in November 2023 (Chugai pharmaceutical pipeline, February 2024)
- 01 Feb 2024 Chugai pharmaceutical announces intention to file regulatory applications for Non-small cell lung cancer (Adjuvant therapy) in Japan in December 2023 (Chugai pharmaceutical pipeline, February 2024)